<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:54:48Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6518443" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6518443</identifier>
        <datestamp>2019-05-28</datestamp>
        <setSpec>frontimmu</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
              <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
              <journal-title-group>
                <journal-title>Frontiers in Immunology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1664-3224</issn>
              <publisher>
                <publisher-name>Frontiers Media S.A.</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6518443</article-id>
              <article-id pub-id-type="pmcid">PMC6518443</article-id>
              <article-id pub-id-type="pmc-uid">6518443</article-id>
              <article-id pub-id-type="pmid">31139182</article-id>
              <article-id pub-id-type="doi">10.3389/fimmu.2019.01005</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Immunology</subject>
                  <subj-group>
                    <subject>Original Research</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Evaluation of Mannose Binding Lectin Gene Variants in Pediatric Influenza Virus-Related Critical Illness</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Levy</surname>
                    <given-names>Emily R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/550498/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yip</surname>
                    <given-names>Wai-Ki</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/624006/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Super</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/607053/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ferdinands</surname>
                    <given-names>Jill M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mistry</surname>
                    <given-names>Anushay J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/488991/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Newhams</surname>
                    <given-names>Margaret M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Yu</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/531175/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Su</surname>
                    <given-names>Helen C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/255247/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McLaughlin</surname>
                    <given-names>Gwenn E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sapru</surname>
                    <given-names>Anil</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/351584/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Loftis</surname>
                    <given-names>Laura L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Weiss</surname>
                    <given-names>Scott L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/631002/overview"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hall</surname>
                    <given-names>Mark W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cvijanovich</surname>
                    <given-names>Natalie</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff12">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schwarz</surname>
                    <given-names>Adam</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff13">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tarquinio</surname>
                    <given-names>Keiko M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mourani</surname>
                    <given-names>Peter M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff15">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>PALISI PICFLU Investigators</collab>
                  <xref ref-type="author-notes" rid="fn002">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Randolph</surname>
                    <given-names>Adrienne G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                  <xref ref-type="corresp" rid="c001">
                    <sup>*</sup>
                  </xref>
                  <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/489246/overview"/>
                </contrib>
              </contrib-group>
              <aff id="aff1"><sup>1</sup><institution>Division of Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital and Department of Anaesthesia, Harvard Medical School</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff>
              <aff id="aff2"><sup>2</sup><institution>Divisions of Pediatric Critical Care and Pediatric Infectious Diseases, Department of Pediatrics, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country>United States</country></aff>
              <aff id="aff3"><sup>3</sup><institution>Foundation Medicine Inc.</institution>, <addr-line>Cambridge, MA</addr-line>, <country>United States</country></aff>
              <aff id="aff4"><sup>4</sup><institution>Wyss Institute at Harvard University</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff>
              <aff id="aff5"><sup>5</sup><institution>Influenza Division, US Centers for Disease Control and Prevention</institution>, <addr-line>Atlanta, GA</addr-line>, <country>United States</country></aff>
              <aff id="aff6"><sup>6</sup><institution>Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country></aff>
              <aff id="aff7"><sup>7</sup><institution>Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Miami Miller School of Medicine</institution>, <addr-line>Miami, FL</addr-line>, <country>United States</country></aff>
              <aff id="aff8"><sup>8</sup><institution>Critical Care Medicine Division, Department of Pediatrics, Children's Hospital of Los Angeles, University of California, Los Angeles</institution>, <addr-line>Los Angeles, CA</addr-line>, <country>United States</country></aff>
              <aff id="aff9"><sup>9</sup><institution>Section of Critical Care Medicine, Department of Pediatrics, Texas Children's Hospital</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff>
              <aff id="aff10"><sup>10</sup><institution>Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia</institution>, <addr-line>Philadelphia, PA</addr-line>, <country>United States</country></aff>
              <aff id="aff11"><sup>11</sup><institution>Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital</institution>, <addr-line>Columbus, OH</addr-line>, <country>United States</country></aff>
              <aff id="aff12"><sup>12</sup><institution>Department of Pediatrics, Benioff Children's Hospital Oakland, University California San Francisco</institution>, <addr-line>Oakland, CA</addr-line>, <country>United States</country></aff>
              <aff id="aff13"><sup>13</sup><institution>Department of Pediatrics, Children's Hospital of Orange County</institution>, <addr-line>Orange, CA</addr-line>, <country>United States</country></aff>
              <aff id="aff14"><sup>14</sup><institution>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children's Healthcare of Atlanta at Egleston, Emory University School of Medicine</institution>, <addr-line>Atlanta, GA</addr-line>, <country>United States</country></aff>
              <aff id="aff15"><sup>15</sup><institution>Section of Critical Care Medicine, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado</institution>, <addr-line>Aurora, CO</addr-line>, <country>United States</country></aff>
              <aff id="aff16"><sup>16</sup><institution>Department of Pediatrics, Harvard Medical School</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff>
              <author-notes>
                <fn fn-type="edited-by">
                  <p>Edited by: Luregn J. Schlapbach, University of Queensland, Australia</p>
                </fn>
                <fn fn-type="edited-by">
                  <p>Reviewed by: Michiel Van Der Flier, Radboud University Medical Center, Netherlands; Lachlan James Coin, University of Queensland, Australia</p>
                </fn>
                <corresp id="c001">*Correspondence: Adrienne G. Randolph <email>adrienne.randolph@childrens.harvard.edu</email></corresp>
                <fn fn-type="other" id="fn001">
                  <p>This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology</p>
                </fn>
                <fn fn-type="other" id="fn002">
                  <p>†PALISI PICFLU Investigators are listed in the acknowledgments</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>08</day>
                <month>5</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>10</volume>
              <elocation-id>1005</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>8</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>4</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2019 Levy, Yip, Super, Ferdinands, Mistry, Newhams, Zhang, Su, McLaughlin, Sapru, Loftis, Weiss, Hall, Cvijanovich, Schwarz, Tarquinio, Mourani, PALISI PICFLU Investigators and Randolph.</copyright-statement>
                <copyright-year>2019</copyright-year>
                <copyright-holder>Levy, Yip, Super, Ferdinands, Mistry, Newhams, Zhang, Su, McLaughlin, Sapru, Loftis, Weiss, Hall, Cvijanovich, Schwarz, Tarquinio, Mourani, PALISI PICFLU Investigators and Randolph</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
                </license>
              </permissions>
              <abstract>
                <p><bold>Background:</bold> Mannose-binding lectin (MBL) is an innate immune protein with strong biologic plausibility for protecting against influenza virus-related sepsis and bacterial co-infection. In an autopsy cohort of 105 influenza-infected young people, carriage of the deleterious MBL gene <italic>MBL2</italic>_Gly54Asp(“B”) mutation was identified in 5 of 8 individuals that died from influenza-methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) co-infection. We evaluated <italic>MBL2</italic> variants known to influence MBL levels with pediatric influenza-related critical illness susceptibility and/or severity including with bacterial co-infections.</p>
                <p><bold>Methods:</bold> We enrolled children and adolescents with laboratory-confirmed influenza infection across 38 pediatric intensive care units from November 2008 to June 2016. We sequenced <italic>MBL2</italic> “low-producer” variants rs11003125(“H/L”), rs7096206(“Y/X”), rs1800450<sub>Gly54Asp</sub>(“B”), rs1800451<sub>Gly57Glu</sub>(“C”), rs5030737<sub>Arg52Cys</sub>(“D”) in patients and biologic parents. We measured serum levels and compared complement activity in low-producing homozygotes (“B/B,” “C/C”) to HYA/HYA controls. We used a population control of 1,142 healthy children and also analyzed family trios (PBAT/HBAT) to evaluate disease susceptibility, and nested case-control analyses to evaluate severity.</p>
                <p><bold>Results:</bold> We genotyped 420 patients with confirmed influenza-related sepsis: 159 (38%) had acute lung injury (ALI), 165 (39%) septic shock, and 30 (7%) died. Although bacterial co-infection was diagnosed in 133 patients (32%), only MRSA co-infection (<italic>n</italic> = 33, 8% overall) was associated with death (<italic>p</italic> &lt; 0.0001), present in 11 of 30 children that died (37%). <italic>MBL2</italic> variants predicted serum levels and complement activation as expected. We found no association between influenza-related critical illness susceptibility and <italic>MBL2</italic> variants using family trios (633 biologic parents) or compared to population controls. <italic>MBL2</italic> variants were not associated with admission illness severity, septic shock, ALI, or bacterial co-infection diagnosis. Carriage of low-MBL producing <italic>MBL2</italic> variants was not a risk factor for mortality, but children that died did have higher carriage of one or more B alleles (OR 2.3; <italic>p</italic> = 0.007), including 7 of 11 with influenza MRSA-related death (vs. 2 of 22 survivors: OR 14.5, <italic>p</italic> = 0.0002).</p>
                <p><bold>Conclusions:</bold><italic>MBL2</italic> variants that decrease MBL levels were not associated with susceptibility to pediatric influenza-related critical illness or with multiple measures of critical illness severity. We confirmed a prior report of higher B allele carriage in a relatively small number of young individuals with influenza-MRSA associated death.</p>
              </abstract>
              <kwd-group>
                <kwd>MBL</kwd>
                <kwd>influenza</kwd>
                <kwd>pediatric</kwd>
                <kwd>methicillin-resistant <italic>Staphylococcus aureus</italic></kwd>
                <kwd>critical illness</kwd>
                <kwd>sepsis</kwd>
                <kwd>mortality</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source>
                </award-group>
                <award-group>
                  <funding-source id="cn002">Centers for Disease Control and Prevention<named-content content-type="fundref-id">10.13039/100000030</named-content></funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="3"/>
                <equation-count count="0"/>
                <ref-count count="58"/>
                <page-count count="12"/>
                <word-count count="8949"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Severe sepsis is the most common cause of death in infants and children across the world (<xref rid="B1" ref-type="bibr">1</xref>). Influenza virus is a common global pathogen causing severe sepsis, and annually leads to 100–350 deaths and over 25,000 hospitalizations in North American children (<xref rid="B2" ref-type="bibr">2</xref>–<xref rid="B4" ref-type="bibr">4</xref>). Influenza suppresses the immune system, allowing respiratory tract colonizers to invade and cause bacterial co-infection, a major contributor to influenza-related morbidity and mortality (<xref rid="B5" ref-type="bibr">5</xref>). In 2003, methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) emerged in the United States as a major co-infecting bacterial organism in children with influenza virus infection and an independent predictor of death (<xref rid="B6" ref-type="bibr">6</xref>). In comparison to healthy adults, children are heavily reliant on innate immunity for protection against influenza virus and bacterial pathogens as they have limited adaptive immunity and fewer years of exposure to develop anti-microbial antibodies (<xref rid="B7" ref-type="bibr">7</xref>).</p>
              <p>The wide spectrum of influenza virus-related disease severity is likely influenced by host genetics. Novel primary immunodeficiencies to influenza and other common viruses have been identified in children previously thought to be healthy (<xref rid="B8" ref-type="bibr">8</xref>–<xref rid="B10" ref-type="bibr">10</xref>). Most are in interferon regulatory genes, essential for innate immunity to viruses (<xref rid="B11" ref-type="bibr">11</xref>). However, other gene pathways may influence disease severity, particularly in relation to bacterial co-infection. Mannose-binding lectin (MBL), a key innate immunity pattern-recognition protein, activates the lectin complement pathway. MBL has strong biologic plausibility as an innate immunity candidate protein that could protect against influenza-related sepsis with and without bacterial co-infection (<xref rid="B12" ref-type="bibr">12</xref>). MBL binds to microbial surface glycosylation residues and targets influenza virus via direct neutralization, by recognition of influenza hemagglutinin surface proteins on infected cells, and can also ameliorate severity by defending against bacterial pathogens (<xref rid="B13" ref-type="bibr">13</xref>–<xref rid="B15" ref-type="bibr">15</xref>). Additionally, influenza virus uses a glycan-binding entry mechanism to invade host cells, and lectins such as MBL may interfere directly with entry of the pathogen into the cell (<xref rid="B16" ref-type="bibr">16</xref>).</p>
              <p>MBL serum levels and functional activity are strongly influenced by five single nucleotide polymorphisms (SNPs) in the <italic>MBL2</italic> gene. As shown in <xref ref-type="fig" rid="F1">Figure 1A</xref>, three <italic>MBL2</italic> missense mutations in Exon 1, “B” (rs1800450_A; codon 54 Gly to Asp), “C” (rs1800451_A; codon 57 Gly to Glu), and “D” (rs5030737_T; codon 52 Arg to Cys), combine with <italic>MBL2</italic> promoter polymorphisms “H/L” and “Y/X” to form low-, intermediate- and high-producing MBL haplotypes (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>) (see <xref ref-type="fig" rid="F1">Figure 1B</xref>). Although all 3 exon mutations are associated with the lowest levels of MBL, only the B variant Asp residue has been reported to destabilize circulating MBL oligomers having a dominant effect when present, further decreasing functional activity (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). MBL deficiency is common, and may occur in 30% of the population depending on what MBL level cutoff is used for defining it; deficiency has been defined variably as &lt;1,000, &lt;500, &lt;200, or &lt;100 ng/mL (<xref rid="B21" ref-type="bibr">21</xref>). In critically ill patients, serum levels may be influenced by inflammation, diluted by fluid resuscitation, or raised via fresh frozen plasma transfusion, so genotype has been used as an inexact proxy to estimate pre-illness MBL deficiency (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B22" ref-type="bibr">22</xref>).</p>
              <fig id="F1" position="float">
                <label>Figure 1</label>
                <caption>
                  <p><bold>(A)</bold><italic>MBL2</italic> gene with known low-producer variant polymorphisms. Marked positions denote promoter variants H/L and Y/X, and exon 1 variants “B,” “C,” and “D” (collectively termed “O”). <bold>(B)</bold> The gene-to-level analysis (<italic>n</italic> = 265) included all genotyped patients who also had measured MBL levels. Box and whisker plots indicate serum level quartiles: 1st quartile (bottom line) 2nd/3rd quartile (box) with median at line, and 4th quartile (top line). <italic>MBL2</italic> haplotypes combined into diplotypes with associated serum MBL levels (<italic>n</italic> = number of patients included); wild type (A/A), heterozygote (A/O), and homozygotes (O/O) with additions of low-producing promoters from left-to-right within each X-axis group. Specific variants within LYO/LYO homozygotes are shown in insert; there were not significant differences in levels among B/B, C/C, and B/C homozygotes. Four patients (3 HYA/LYA, 1 LYA/LXA) had values &gt; the Y axis set maximum of 4,500 ng/mL. Dashed line indicates 500 ng/mL throughout.</p>
                </caption>
                <graphic xlink:href="fimmu-10-01005-g0001"/>
              </fig>
              <p>Many studies have evaluated the association between MBL genotypes and sepsis, with most comparing carriage of low-MBL producing mutations in B, C or D mutation in exon 1 (termed “O”) to wild-type (“A”), but the studies have shown conflicting and inconclusive results (<xref rid="B23" ref-type="bibr">23</xref>). A limited number of small studies have evaluated associations between MBL and influenza-related critical illness. Herrera-Ramos <italic>et al</italic> reported no increased frequency of low-producing MBL genotypes in 93 adult Spanish inpatients and outpatients infected with 2009 pandemic H1N1 (H1N1<sub>pdm</sub>09) (<xref rid="B24" ref-type="bibr">24</xref>) Higher MBL serum levels were associated with mortality in 27 influenza H1N1<sub>pdm</sub>09-infected critically ill adults (<xref rid="B25" ref-type="bibr">25</xref>) whereas 12 critically ill pediatric patients had lower levels compared to ward patients (<xref rid="B26" ref-type="bibr">26</xref>). A case series comparing <italic>MBL2</italic> genotypes in 100 fatal pediatric influenza cases (from autopsy samples) with a pediatric population control cohort did not find differences in the frequency of <italic>MBL2</italic> variants known to influence MBL levels after stratifying by ethnicity, but fatal influenza cases with MRSA co-infection were more likely to carry the B mutation (<xref rid="B27" ref-type="bibr">27</xref>).</p>
              <p>The 2017 World Health Organization Public Health Research Agenda emphasized that identifying host genetic factors influencing influenza susceptibility and severity is paramount for targeting prevention and identifying novel therapeutics (<xref rid="B28" ref-type="bibr">28</xref>). MBL repletion is feasible (<xref rid="B29" ref-type="bibr">29</xref>) for influenza-infected children predicted to have low or deficient levels. Identification of associations between MBL variants known to influence levels, influenza-related sepsis, and bacterial co-infection could allow opportunities for precision diagnostics and interventions. Therefore, we evaluated associations between <italic>MBL2</italic> variants and overall influenza susceptibility, severity, and bacterial co-infection in a multicenter prospective cohort of critically ill children and adolescents in the Pediatric Intensive Care Influenza (PICFLU) Study.</p>
            </sec>
            <sec sec-type="materials and methods" id="s2">
              <title>Materials and Methods</title>
              <p>From November 2008 through June 2016, the PICFLU Study prospectively enrolled patients (&lt;21 years of age) admitted to 38 PICUs in the Pediatric Acute Lung Injury and Sepsis Investigator's (PALISI) Network with suspected or confirmed community-acquired influenza infection. Details of the PICFLU Study design have been previously published (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Beginning in fall 2010, patients with known risk factors for becoming severely ill with influenza virus such as immunodeficiency, severe chronic lung or heart conditions, were excluded to enrich for identification of genetic susceptibility factors. Testing for influenza virus and other viral pathogens was performed at the enrolling site and in collected respiratory samples using sensitive PCR testing (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Bacterial co-infection was defined as a diagnosis at the clinical site with microbiologic identification of the pathogen within 72 h prior to or after PICU admission (to exclude hospital-acquired infection). Cultures had to come from a sterile site: endotracheal or bronchoscopic specimen, bloodstream or pleural fluid (<xref rid="B31" ref-type="bibr">31</xref>). Patients were defined as previously healthy if they had no underlying comorbidities and were on no chronic medications. Sepsis was defined using the 2005 International Consensus Conference on Pediatric Sepsis criteria (<xref rid="B32" ref-type="bibr">32</xref>). Illness severity was assessed by the Pediatric Risk of Mortality (PRISM) III Score (<xref rid="B33" ref-type="bibr">33</xref>). The American European Consensus Conference Criteria were used for diagnosis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) (<xref rid="B34" ref-type="bibr">34</xref>). We collected samples from pediatric patients (blood) and their parents (saliva). Blood was collected as close to admission as possible and used both for DNA extraction and MBL serum level measurements. Each enrolling site received site Institutional Review Board approval. Written informed consent was obtained from a parent or legal guardian for patients and for each parent contributing their own sample for DNA. The population control cohort included healthy adolescents (12–19 years old) from the National Health and Nutrition Examination Survey (NHANES) (<xref rid="B35" ref-type="bibr">35</xref>) who had <italic>MBL2</italic> genotyping available (<xref rid="B27" ref-type="bibr">27</xref>).</p>
              <sec>
                <title>Serum MBL Evaluation, MBL2 Genotyping, and MBL Functional Assessment</title>
                <p>Genomic DNA from peripheral blood was extracted using the Gentra Puregene Blood kit (Qiagen). Saliva samples were collected using Oragene Saliva kits (DNA Genotek Inc., Ontario, Canada). DNA extraction followed manufacturer's recommendations. We used TaqMan assays to genotype samples for single nucleotide polymorphism (SNPs) using the TaqMan OpenArray® SNP Genotyping Platform (Applied Biosystems, Foster City, CA). We genotyped the following SNPs known to influence MBL levels from both patients and biologic parents: rs7096206 (“Y/X”), rs11003125 (“H/L”), rs1800450_A<sub>Gly54Asp</sub> (allele “B”), rs1800451_A<sub>Gly57Glu</sub> (allele “C”), and rs5030737_T<sub>Arg52Cys</sub> (allele “D”) (see <xref ref-type="fig" rid="F1">Figure 1A</xref>).</p>
                <p>To identify rare deleterious variants in <italic>MBL2</italic>, we performed targeted re-sequencing of the exons and nearby regions using Illumina TruSeq Custom Amplicon kit (TSCA, Illumina, San Diego, CA) as described previously (<xref rid="B30" ref-type="bibr">30</xref>), and this was compared with Taqman genotyping. In samples where genotyping remained inconclusive, Sanger sequencing for the 5 SNPs in <italic>MBL2</italic> was performed.</p>
                <p>For patients enrolled prior to May 2014, MBL serum level measurements were done at the Cytokine Reference Laboratory using a commercial enzyme-linked immunosorbent assay kit from R&amp;D Systems (Minneapolis, MN).</p>
                <p>MBL protein activity was evaluated by measuring lectin pathway complement fixation in the sera of homozygote patients, either “B/B” (<italic>n</italic> = 4) or “C/C” (<italic>n</italic> = 2), and compared to wild type controls (HYA/HYA; <italic>n</italic> = 6). There were no “D/D” homozygotes for evaluation. Dilutions of patient and control sera were incubated on mannan (Sigma M7504) coated plates in Tris buffered saline with Tween and 5 mM CaCl2 (Boston Bioproducts). After incubation at 37°C and rinsing, deposited C3 fragments were detected with HRP-labeled polyclonal sheep anti-human C3c (BioRad 2222-6604P) and measured by ELISA. Lectin pathway activity was determined by comparing absorbance at 450 nm of C3c bound to mannan from patient sera as previously described (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>).</p>
              </sec>
              <sec>
                <title>Statistical Analyses</title>
                <p><italic>MBL2</italic> genotypes were correlated with MBL serum levels to ensure that previously described (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B38" ref-type="bibr">38</xref>) relationships between <italic>MBL2</italic> variants and serum MBL levels were present in the PICFLU cohort. A multiple linear regression model, adjusting for gender, bacterial co-infection, age, race, and influenza status, was used to evaluate associations between variant alleles and serum levels. Frequencies of allele distribution were also compared between influenza virus subgroups (H1N1<sub>pdm</sub>09 versus non-H1N1<sub>pdm</sub>09; influenza A vs. B) and racial groups (all races, white only, white non-Hispanic). Categorical variables were compared using Chi-square test or Fisher's Exact Tests and continuous variables with the Wilcoxon-Mann-Whitney test.</p>
                <p><italic>MBL2</italic> variant frequencies vary by ethnicity and race. To control for possible confounding by population substructure, we used family-based analyses (PBAT/HBAT) (<xref rid="B39" ref-type="bibr">39</xref>–<xref rid="B41" ref-type="bibr">41</xref>) based on the Transmission Disequilibrium Test (TDT) in family trios. When analyzing family trios, only heterozygous parents are included, expected to transmit either alleles 50% of the time to their children. Significantly increased/decreased allele transmission above 50% is defined as transmission disequilibrium. A positive TDT test suggests that the gene itself influences susceptibility to the disease or is in tight linkage with the disease-predisposing gene (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B41" ref-type="bibr">41</xref>). The software (<ext-link ext-link-type="uri" xlink:href="http://www.hsph.harvard.edu/fbat">www.hsph.harvard.edu/fbat</ext-link>) was used to analyze the pedigrees using the PBAT test for individual variants and statistical power estimation and HBAT for <italic>MBL2</italic> haplotypes (minimum informative families = 10), first testing the additive model, with follow-up testing of dominant and recessive models.</p>
                <p>We compared <italic>MBL2</italic> variant frequencies in PICFLU to a population control cohort of healthy children (12–19 years old), from the National Health and Nutrition Examination Survey (NHANES) (<xref rid="B35" ref-type="bibr">35</xref>) who had MBL genotyping available (<xref rid="B27" ref-type="bibr">27</xref>). We stratified the comparison by the racial groups reported in NHANES (white non-Hispanic, Black non-Hispanic and white Hispanic). We tested for Hardy Weinberg equilibrium in each subgroup and compared frequencies using the allelic test (using Rx64 3.2.1 software package) (<xref rid="B42" ref-type="bibr">42</xref>).</p>
                <p>In the severity analysis, we a utilized a whole genome association analysis toolset called PLINK (<xref rid="B43" ref-type="bibr">43</xref>) (available at <ext-link ext-link-type="uri" xlink:href="https://pngu.mgh.harvard.edu/~purcell/plink/">https://pngu.mgh.harvard.edu/~purcell/plink/</ext-link>) that uses Chi-square or Fishers Exact tests to evaluate allele and genotype associations. We evaluated associations between the five individual <italic>MBL2</italic> alleles and severity phenotypes using the allelic test (<xref rid="B42" ref-type="bibr">42</xref>). Data were analyzed in the entire genotyped cohort, as well as in the major racial ethnic subgroup (white non-Hispanics) to exclude confounding by population admixture. Severity markers included the continuous PRISM-III admission illness severity score (<xref rid="B33" ref-type="bibr">33</xref>) (untransformed and Log transformed) and the dichotomous outcomes of ALI/ARDS, extracorporeal life support (ELS), bacterial co-infection, septic shock, and hospital mortality.</p>
                <p>To control for multiple comparisons, we used a Bonferroni corrected <italic>p</italic>-value critical value of 0.0083 (0.05/6) adjusted for 5 <italic>MBL2</italic> variants making 6 haplotypes that were tested. Although this adjustment may not be sufficiently stringent given the number of phenotypes tested, the severity phenotypes were not independent.</p>
                <p>A priori, we planned to test for interactions with other reported genetic associations in PICFLU, which was with <italic>IFITM3</italic> rs34481144 and mortality (<xref rid="B11" ref-type="bibr">11</xref>). IFITM3 rs12252 was not associated with influenza susceptibility or severity in PICFLU (<xref rid="B30" ref-type="bibr">30</xref>). We also recently reported higher mortality in children with influenza-MRSA co-infection with vancomycin monotherapy vs. dual anti-MRSA coverage (<xref rid="B31" ref-type="bibr">31</xref>). So we used Gaussian linear modeling to check for interaction with antibiotic therapy and associated alleles using the lm function in the R basic statistical library (<xref ref-type="supplementary-material" rid="SM3">Supplemental Table 3</xref>). We did not correct for multiple comparisons in these secondary analyses.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <p>We enrolled and genotyped 420 children with confirmed influenza-related critical illness; 333 (80%) had influenza A infection (41% H1N1<sub>pdm</sub>09, 15% H3N2, 23% other), and 81 (19%) had influenza B infection. <xref rid="T1" ref-type="table">Table 1</xref> lists the demographic characteristics and clinical course of the patients, including comorbid conditions and complications. Of the 420 children, 159 (38%) developed ALI/ARDS, 165 (39%) developed septic shock requiring vasopressors and 30 patients died (7%). Influenza-MRSA co-infection was present in 33 of 420 children in the cohort (8%) and was a risk factor for mortality (<italic>p</italic> &lt; 0.0001) present in 37% of fatalities but only 6% of survivors. Influenza-MSSA co-infection was identified in 41 children (10%), but was present approximately equally (~10%) in deaths and survivors (<italic>p</italic> = 0.1)</p>
              <table-wrap id="T1" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Demographic and clinical characteristics, clinical course, and outcomes of the critically ill children in the PICFLU cohort including a comparison of those with fatal vs. non-fatal infection.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th valign="top" align="center" style="border-bottom: thin solid #000000;" rowspan="1" colspan="1">
                        <bold>Total</bold>
                      </th>
                      <th valign="top" align="center" style="border-bottom: thin solid #000000;" rowspan="1" colspan="1">
                        <bold>Fatal</bold>
                      </th>
                      <th valign="top" align="center" style="border-bottom: thin solid #000000;" rowspan="1" colspan="1">
                        <bold>Survived</bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold><italic>P</italic>-Value<xref ref-type="table-fn" rid="TN4"><sup>∧</sup></xref></bold>
                      </th>
                    </tr>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold>(N = 420)</bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold>(N = 30)</bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold>(N = 390)</bold>
                      </th>
                      <th rowspan="1" colspan="1"/>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Female, N (%)</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">163 (38.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">14 (46.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">149 (38.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.4</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Hispanic, N (%)</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">113 (26.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11 (36.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">102 (26.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.2</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Race, N (%)</bold>
                      </td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.3</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  White</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">305 (72.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">22 (73.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">283 (72.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.9</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  African-American</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">64 (15.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (6.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">62 (15.9)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Asian</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">14 (3.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (3.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">13 (3.3)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Mixed or Other</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">37 (8.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (16.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">32 (8.2)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Age, years, med (IQR)</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6.5 (2.4, 11.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">10.1 (1.7, 14.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6.3 (2.4, 10.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.09</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Baseline Health Status<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref>, N (%)</bold>
                      </td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Previously Healthy</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">226 (53.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">17 (56.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">209 (53.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.7</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Respiratory<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">140 (33.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (13.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">136 (34.9)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Immune Compromised<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (1.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (10.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (0.8)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Other<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">177 (42.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">13 (43.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">164 (42.1)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Support and Complications, N (%)</bold>
                      </td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Acute Lung Injury</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">159 (37.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">23 (76.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">136 (34.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>&lt;0.0001</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Myocarditis</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11 (2.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (10.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8 (2.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.04</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Encephalitis</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">10 (2.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">10 (2.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Shock Receiving Vasopressors</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">165 (39.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">138 (35.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">27 (90.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>&lt;0.0001</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Extracorporeal Life Support</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">46 (11.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">17 (56.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">29 (7.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>&lt;0.0001</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>PRISM Score, median (IQR)</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B11" ref-type="bibr">11</xref>)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">26.5 (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B34" ref-type="bibr">34</xref>)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B10" ref-type="bibr">10</xref>)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>&lt;0.0001</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Bacterial Co-infection<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref>, N (%)</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">133 (31.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">18 (60.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">115 (29.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>0.0005</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Methicillin-resistant <italic>S. aureus</italic></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">33 (7.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11 (36.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">22 (5.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>&lt;0.0001</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Methicillin-resistant <italic>S. aureus</italic></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">41 (9.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (10.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">38 (9.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  <italic>Streptococcus pneumoniae</italic></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">16 (3.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (3.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">15 (3.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Other Bacteria</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">50 (11.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (10.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">47 (12.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Viral Co-infection, N (%)</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">94 (22.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (20.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">88 (22.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.7</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Influenza Type, N<xref ref-type="table-fn" rid="TN3"><sup>***</sup></xref></bold>
                        <bold>(%)</bold>
                      </td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Influenza A</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">333 (79.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">22 (73.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">311 (80.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.4</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">H1N1<sub>pdm</sub>09</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">170 (40.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12 (40.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">158 (40.5)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">H3N2</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">68 (16.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (13.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">64 (16.4)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Other or no subtype</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">95 (22.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (20.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">89 (22.8)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Influenza B</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">81 (19.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8 (26.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">73 (18.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.3</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Influenza A and B</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (0.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (0.5)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TN1">
                    <label>*</label>
                    <p>Children could have multiple underlying medical conditions and</p>
                  </fn>
                  <fn id="TN2">
                    <label>**</label>
                    <p><italic>multiple bacterial co-infections</italic>.</p>
                  </fn>
                  <fn id="TN3">
                    <label>***</label>
                    <p><italic>4 patients were Influenza positive with subtype unknown</italic>.</p>
                  </fn>
                  <fn id="TN4">
                    <label>∧</label>
                    <p><italic>p-values compare Fatal vs. Survived groups. Bolded values are statistically significant</italic>.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The subgroup of 265 patients enrolled prior to May 2014 with available MBL levels had similar demographics and clinical characteristics to the full cohort. The median MBL level was 1,076 ng/ml (interquartile range [IQR] 666–1,894 ng/mL; range 71–7,028). Forty-four patients had levels &lt;500 and 3 patients had levels &lt;100 ng/ml. As shown in <xref ref-type="fig" rid="F1">Figure 1B</xref>, as would be expected wild type (HYA/HYA) diplotypes had the highest levels (median 2,155; IQR 1,698–2,488) and homozygotes for an “O” (B, C, or D) allele had the lowest levels (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Using multiple linear regression adjusted for sex, race and age, on average, each promoter L variant carried was predicted to decrease MBL levels by 12% (<italic>p</italic> = 0.04), each promoter X by 35% (<italic>p</italic> &lt; 0.001), and each O allele (B, C, or D) by 56% (<italic>p</italic> &lt; 0.001, full regression model shown in <xref ref-type="supplementary-material" rid="SM1">Supplemental Table 1</xref>).</p>
              <p>The results of the <italic>in vitro</italic> complement fixation analysis are shown in <xref ref-type="fig" rid="F2">Figure 2</xref>. Homozygote B/B or C/C serum had minimal fixation of C3c complement, including those patients with measured serum levels of &gt;500. There were no D/D homozygotes to test. High MBL producing (wild type) controls (HYA/HYA) fixed complement at expected dilutions (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>).</p>
              <fig id="F2" position="float">
                <label>Figure 2</label>
                <caption>
                  <p>Complement (C3c) fixation by ELISA. Controls (HYA/HYA) fixed complement at typical absorbance (450 nm) measurements despite serial dilutions. Homozygotes [rs1800450<sub>Gly54Asp</sub>(B/B) and rs1800451<sub>Gly57Glu</sub>(C/C)] had markedly reduced complement activation. Bars above and below data points indicate standard deviation. Patients with measured serum levels available have numerical (ng/mL) levels labeled on right. There were no rs5030737<sub>Arg52Cys</sub>(D/D) homozygotes in the population.</p>
                </caption>
                <graphic xlink:href="fimmu-10-01005-g0002"/>
              </fig>
              <p>Targeted re-sequencing of the <italic>MBL2</italic> exons identified a rare deleterious variant in a white Hispanic patient who had an MBL serum level below the assay's detectable limits (&lt;3.2 ng/mL). This patient was excluded from the gene-to-level analyses. The patient had an HYA/LYA genotype so was predicted to be a high-MBL producer (see <xref ref-type="fig" rid="F1">Figure 1B</xref>). However, he was homozygous for rs74754826 which creates a premature stop codon at aa210 leading to null production of MBL. According to the gnomAD database (gnomAD r2.0.2), the variant is not usually identified in populations of European or Hispanic origin and is overall rare (frequency 0.0006, <ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/variant/10-54528016-C-A">http://gnomad.broadinstitute.org/variant/10-54528016-C-A</ext-link>) with a relatively higher frequency in populations of African origin (MAF = 0.006). The patient was born prematurely and the respiratory viral culture grew cytomegalovirus at time of influenza diagnosis. The patient had recurrent upper and lower respiratory infections before admission and after discharge. We identified no other individuals with rare, potentially deleterious mutations in <italic>MBL2</italic>.</p>
              <p>The results of the individual SNP (PBAT) and haplotype (HBAT) family-based analyses are shown in <xref rid="T2" ref-type="table">Table 2</xref>. Estimated statistical power in PBAT was acceptable for low MBL-producing variants (X, B, C, and D) but not for the L variant, which is in tight linkage with the other low-producing variants and has minimal influence on MBL levels by itself. From 633 available parents there were 252 nuclear families. Due to high linkage disequilibrium, the five variant alleles combined into six common (≥5% frequency) haplotypes with the X, B, C, and D alleles each represented by one haplotype (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B38" ref-type="bibr">38</xref>). No transmission disequilibrium was detected for MBL variants or haplotypes (<italic>p</italic> ≥ 0.06 for all analyses).</p>
              <table-wrap id="T2" position="float">
                <label>Table 2</label>
                <caption>
                  <p>Results of the Family Based Association Test Analysis in children with influenza using PBAT for individual SNPs and HBAT for haplotypes.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th valign="top" align="left" rowspan="1" colspan="1">
                        <bold>SNP (allele)</bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold>Frequency</bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold>Families</bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold><italic>Z</italic>-Score</bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold><italic>P</italic>-value<xref ref-type="table-fn" rid="TN6"><sup>∧</sup></xref></bold>
                      </th>
                      <th valign="top" align="center" rowspan="1" colspan="1">
                        <bold>Power<xref ref-type="table-fn" rid="TN5"><sup>*</sup></xref></bold>
                      </th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">H (rs11003125)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.39</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">166</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">−1.74</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.08</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.05</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">L</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.61</td>
                      <td rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1">+1.74</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Y (rs7096206)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.84</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">126</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">−0.34</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.73</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">X</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.16</td>
                      <td rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1">+0.34</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">B (rs1800450)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.14</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">104</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">+1.66</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.10</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Wild Type</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.86</td>
                      <td rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1">−1.66</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">C (rs1800451)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.05</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">36</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">−1.76</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.08</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Wild Type</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.95</td>
                      <td rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1">+1.76</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">D (rs5030737)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.05</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">51</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">−0.14</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.89</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Wild Type</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.95</td>
                      <td rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1">+0.14</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr style="border-top: thin solid #000000;">
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Haplotype</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>Frequency</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <bold>Families</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <italic>
                          <bold>Z</bold>
                        </italic>
                        <bold>-Score</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1">
                        <italic>
                          <bold>P</bold>
                        </italic>
                        <bold>-value</bold>
                        <xref ref-type="table-fn" rid="TN6">
                          <sup>∧</sup>
                        </xref>
                      </td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr style="border-top: thin solid #000000;">
                      <td valign="top" align="left" rowspan="1" colspan="1">HYA</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.34</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">158</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">−1.73</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.08</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">–</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYA</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.25</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">151</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.75</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.45</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">–</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">LXA</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.16</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">121</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.53</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.60</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">–</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYB</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.14</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">97</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.88</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.06</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">–</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYC</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.05</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">31</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">−1.72</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.09</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">–</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">HYD</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.05</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">45</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.17</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.87</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">–</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TN5">
                    <label>*</label>
                    <p><italic>Calculated using the Additive Model in PBAT</italic>.</p>
                  </fn>
                  <fn id="TN6">
                    <label>∧</label>
                    <p><italic>p-values are using the Additive Model</italic>.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p><xref ref-type="fig" rid="F3">Figure 3</xref> shows the <italic>MBL2</italic> variant frequencies in the PICFLU cohort (for whom self-reported race and ethnicity were available, <italic>n</italic> = 357) compared to the NHANES pediatric population (<italic>n</italic> = 1,142) sub-grouped by race and ethnicity (data provided in <xref ref-type="supplementary-material" rid="SM2">Supplemental Table 2</xref> and individual patient data available upon request). No significant differences were identified (all <italic>p</italic> &gt; 0.05). HWE was <italic>p</italic> &gt; 0.05 in all subgroups except the X allele was out of HWE in the white Hispanic NHANES controls.</p>
              <fig id="F3" position="float">
                <label>Figure 3</label>
                <caption>
                  <p>PICFLU MBL variant frequencies, compared with NHANES pediatric population reference, by ethnicity/racial subgroups. Frequencies of all variants were similar (<italic>p</italic> &gt; 0.05 for all comparisons). The calculated 95% confidence interval around the allelic point estimate is shown.</p>
                </caption>
                <graphic xlink:href="fimmu-10-01005-g0003"/>
              </fig>
              <p>In the severity analyses, none of the individual <italic>MBL2</italic> variants were associated with overall illness severity (PRISM III score), or with frequency of shock requiring vasopressors, ALI, or bacterial co-infection (all <italic>p</italic> &gt; 0.05). Carriage of the B missense mutation was higher in children that died. As shown in <xref ref-type="fig" rid="F4">Figure 4A</xref>, in children that died 47% (14/30) carried at least one B mutation compared to 26% (100 of 390) survivors (OR 2.3, <italic>p</italic> = 0.007 overall; white non-Hispanics <italic>n</italic> = 217, OR 2.9, <italic>p</italic> = 0.007). The B mutation was not associated with the frequency of MRSA co-infection (<italic>p</italic> = 0.65, <xref ref-type="fig" rid="F4">Figure 4B</xref>). MRSA co-infection was a risk factor for death, however, and 64% (<italic>n</italic> = 7/11) of children with influenza-MRSA co-infection that died carried at least one B mutation compared to 9% (2/22) survivors with influenza-MRSA co-infection (OR 14.5; <italic>p</italic> = 0.0002; see <xref ref-type="fig" rid="F4">Figure 4C</xref>). In influenza-infected children who died without MRSA co-infection, 37% (<italic>n</italic> = 7/19) carried at least one B mutation compared to 27% (<italic>n</italic> = 98/368) of survivors (OR 1.3, <italic>p</italic> = 0.49, see <xref ref-type="fig" rid="F4">Figure 4D</xref>).</p>
              <fig id="F4" position="float">
                <label>Figure 4</label>
                <caption>
                  <p><bold>(A)</bold> Distribution of rs1800450<sub>Gly54Asp</sub>(B) in children with influenza critical illness who died or survived (numbers shown) to hospital discharge in all children (<italic>n</italic> = 420). Mortality was higher in all children carrying at least one copy of the rs1800450<sub>Gly54Asp</sub>(B) allele (<italic>p</italic> = 0.007). <bold>(B)</bold> Distribution of rs1800450<sub>Gly54Asp</sub>(B) in children with and without methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) co-infection. There was no association with risk of contracting MRSA co-infection (<italic>p</italic> = 0.65). However, sub-analysis of deaths in patients with MRSA co-infection compared to those without MRSA co-infection showed a strong association of rs1800450<sub>Gly54Asp</sub>(B) with mortality in the patients with MRSA co-infection. <bold>(C)</bold> rs1800450<sub>Gly54Asp</sub>(B) Association with MRSA Co-infection Died vs. MRSA Co-infection Survived (<italic>p</italic> = 0.0002). <bold>(D)</bold> No MRSA Died vs. No MRSA Survived (<italic>p</italic> = 0.49).</p>
                </caption>
                <graphic xlink:href="fimmu-10-01005-g0004"/>
              </fig>
              <p>The characteristics and clinical course of the 11 children that died with influenza-MRSA co-infection are shown in <xref rid="T3" ref-type="table">Table 3</xref>. All children received fluid resuscitation for severe shock and required vasopressors. Ten (91%) were supported via extracorporeal life support (ELS) before death. Although older age was associated with mortality (see <xref rid="T1" ref-type="table">Table 1</xref>), age was not associated with B allele carriage (<italic>p</italic> = 0.48) so it was not a confounder. The B allele was also not associated with <italic>IFITM3</italic> variant rs34481144 which we previously reported was associated with mortality in PICFLU (<xref rid="B11" ref-type="bibr">11</xref>).</p>
              <table-wrap id="T3" position="float">
                <label>Table 3</label>
                <caption>
                  <p>Characteristics and <italic>MBL2</italic> genotype and MBL level (when available) of children with fatal influenza MRSA co-infection in the PICFLU cohort.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Age group/gender</bold>
                      </th>
                      <th valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Influenza type</bold>
                      </th>
                      <th valign="top" align="left" rowspan="1" colspan="1">
                        <bold><italic>MBL2</italic> haplotype</bold>
                      </th>
                      <th valign="top" align="left" rowspan="1" colspan="1">
                        <bold><italic>MBL2</italic> mutation</bold>
                      </th>
                      <th valign="top" align="left" rowspan="1" colspan="1">
                        <bold>MBL level</bold>
                      </th>
                      <th valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Risk factors<xref ref-type="table-fn" rid="TN7"><sup>∧</sup></xref></bold>
                      </th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza B</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">HYA/LYB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800450 (B)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1063<xref ref-type="table-fn" rid="TN8"><sup>*</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Female</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza A H3</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">HYA/LYB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800450 (B)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Not available</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza B</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LXA/LYB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800450 (B)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">666<xref ref-type="table-fn" rid="TN8"><sup>*</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza B</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LXA/LYB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800450 (B)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">570</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza B</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYB/LYC</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800450 (B), rs1800451 (C)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">338<xref ref-type="table-fn" rid="TN8"><sup>*</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">5–12 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza A(H1N1)pdm09</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYB/LYB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800450 (B/B)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1025<xref ref-type="table-fn" rid="TN8"><sup>*</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza A(H1N1)pdm09</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYB/LYB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800450 (B/B)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Not available</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza A H3</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYC/LYC</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">rs1800451 (C/C)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">707</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Female</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza B</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">HYA/HYA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">none</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1417<xref ref-type="table-fn" rid="TN8"><sup>*</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">5–12 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza A(H1N1)pdm09</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYA/LYA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">none</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1042<xref ref-type="table-fn" rid="TN9"><sup>**</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">13–18 yrs/Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Influenza A(H1N1)pdm09</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">LYA/LYA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">none</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">708<xref ref-type="table-fn" rid="TN8"><sup>*</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Asthma</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p><italic>Carriage of one or more copies of the rs1800450(B) allele was present in 7 of the 11 children</italic>.</p>
                  <fn id="TN7">
                    <label>∧</label>
                    <p><italic>All patients were intubated, and met criteria for both shock and ARDS. All patients except one received extracorporeal life support (ELS) prior to death</italic>.</p>
                  </fn>
                  <fn id="TN8">
                    <label>*</label>
                    <p>MBL levels measured after initiation of ELS or</p>
                  </fn>
                  <fn id="TN9">
                    <label>**</label>
                    <p><italic>unknown when MBL level measured in relationship to ELS initiation</italic>.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>We previously published an association between vancomycin monotherapy and death in influenza-MRSA co-infected patients (<xref rid="B31" ref-type="bibr">31</xref>), therefore in a secondary analysis we evaluated antibiotic monotherapy as a potential explanation for the association of the B mutation carriage and death. There was no association between carriage of a B mutation and the number (monotherapy vs. two or more) of anti-MRSA antibiotics received in the first 24 h of PICU admission (<italic>p</italic> = 0.44). Multiple logistic regression confirmed an association between anti-MRSA monotherapy and increased mortality (<italic>p</italic> = 0.007) and an independent mortality association with carriage of one B mutation (<italic>p</italic> = 0.0007). There were only two BB homozygotes with MRSA co-infection and both died, precluding comparison.</p>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>In North American children and adolescents admitted to the PICU with influenza virus infection during the 2008 to 2016 influenza seasons, <italic>MBL2</italic> variants predicting low MBL levels did not explain disease susceptibility. The four <italic>MBL2</italic> low-producing variants did influence MBL serum levels and the B and C alleles decreased MBL functional activity as previously described (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Carriage of low-producing <italic>MBL2</italic> variants was not associated with higher disease severity on admission, with development of ALI or shock, or with diagnosis of bacterial co-infection. MBL deficiency does not appear to confer higher risk for severe influenza infection or influenza-related complications.</p>
              <p>We found MBL did not increase susceptibility to severe influenza infection in pediatric patients. Overall, the literature on whether low MBL predisposes to severe infections is conflicting. A systematic review and meta-analysis of studies published before 2013 (<xref rid="B23" ref-type="bibr">23</xref>) reported increased risk of sepsis susceptibility in children carrying an “O” (B, C, or D) variant and in white adults carrying a B mutation (<xref rid="B23" ref-type="bibr">23</xref>). Subsequently, a large study of 1,839 European adults with sepsis from community acquired pneumonia (viral and/or bacterial) or peritonitis showed no association between low-producing <italic>MBL2</italic> variants and infection susceptibility or severity (<xref rid="B44" ref-type="bibr">44</xref>). Similarly, a meta-analysis of 5 pediatric studies showed that the B allele was not a risk factor for recurrent respiratory infections in children (<xref rid="B45" ref-type="bibr">45</xref>). A meta-analysis of 7 neonatal studies (mostly premature infants) associated low MBL, using levels and predictive variants, with development of sepsis (<xref rid="B46" ref-type="bibr">46</xref>). Population-based birth cohort studies showed no increased risk of invasive (bacteremia or meningitis) meningococcal (<xref rid="B47" ref-type="bibr">47</xref>) or pneumococcal (<xref rid="B48" ref-type="bibr">48</xref>) disease in Danish children carrying low-producing <italic>MBL2</italic> variants. A large cohort of hospitalized children with meningococcemia also did not have higher carriage of O alleles (<xref rid="B49" ref-type="bibr">49</xref>). In single center nested case-control PICU studies, we reported no differences in carriage of low-producing <italic>MBL2</italic> variants in patients with severe infections (<xref rid="B22" ref-type="bibr">22</xref>) but others reported a 2-fold overall increase in carriage of the O allele with an increase in homozygotes (<xref rid="B50" ref-type="bibr">50</xref>). Although <italic>MBL2</italic> haplotypes associated with deficiency appear to be a risk factor for a range of infections in neonates or other immune compromised patients, our study adds to the literature that carriage of low-producing <italic>MBL2</italic> variants does not increase risk of severe viral infections (<xref rid="B51" ref-type="bibr">51</xref>). We did identify one child carrying an extremely rare, highly deleterious mutation in <italic>MBL2</italic>, further adding to the literature that rare variants play some role in severe influenza infection susceptibility (<xref rid="B8" ref-type="bibr">8</xref>).</p>
              <p>We report an association with influenza virus-related mortality and increased carriage of the B mutation in PICFLU, primarily limited to children with MRSA co-infection. The study that stimulated us to evaluate MBL was a pediatric autopsy series reporting of increased carriage of the B mutation in children dying from influenza-MRSA co-infection (<xref rid="B27" ref-type="bibr">27</xref>). The autopsy cohort had no survivors for comparison, but 56% (<italic>n</italic> = 5/8) of children dying from influenza-MRSA carried a B mutation (<xref rid="B27" ref-type="bibr">27</xref>), significantly higher than the ~14% expected across the population. Similarly, in PICFLU 64% of children dying from influenza-MRSA co-infection carried the B allele (<italic>n</italic> = 7) compared to 9% of children who survived the co-infection. However, the number of influenza-MRSA deaths carrying the B allele across both studies is only 12, precluding any strong conclusions. The association should not be specific to MRSA. Carriage of the B allele was not higher overall in children with influenza-MRSA co-infection. Prior reports of the association of MBL deficiency and death have not been replicated. Eisen et al. combined individual patient data from 4 studies in a meta-analysis, using &lt;500 ng/uL to define deficiency, and reported that deficiency increased the risk of death from <italic>Streptococcus pneumoniae</italic> (<xref rid="B52" ref-type="bibr">52</xref>). A subsequent study did not replicate this finding (<xref rid="B44" ref-type="bibr">44</xref>). The complement system is redundant, which may lead to contradictory results from evaluation of MBL2 variants across different populations. Contradictory results could also be because increased inflammation from complement activation from high-MBL production could make low-producing MBL2 genotypes protective (<xref rid="B53" ref-type="bibr">53</xref>). However, in contrast to reports in adult patients, we saw no evidence of increased lung disease severity (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B54" ref-type="bibr">54</xref>). or organ dysfunction (<xref rid="B55" ref-type="bibr">55</xref>) in children and adolescents with higher MBL. Overall, MBL levels in our population were higher than expected for carriers of an O allele (<xref rid="B56" ref-type="bibr">56</xref>), which are usually predicted to be &lt;200 ng/ml (<xref rid="B21" ref-type="bibr">21</xref>). This may be secondary to fresh-frozen plasma administration (<xref rid="B29" ref-type="bibr">29</xref>) during critical illness or from inflammatory phase elevation.</p>
              <p>The PICFLU cohort is a major strength of this study, including children and adolescents with influenza critical illness from multiple centers with rigorous diagnostic testing and phenotyping. The majority of children were previously healthy, including almost all of those that died, increasing the ability to identify genetic influences in severe influenza infection. The inclusion of parental DNA facilitated family-based association testing. Use of sera from the influenza-infected homozygote patients allowed us to verify that variant MBL markedly decreased complement activity. We used a rigorous diagnosis of bacterial co-infection requiring microbiologic confirmation and clinical diagnosis. Although we did not have sufficient sera to demonstrate decreased anti-influenza activity in low-MBL producer variants, this has been shown previously (<xref rid="B13" ref-type="bibr">13</xref>). This study was <italic>a priori</italic> designed evaluate the association of MBL and other candidate genes with influenza infection, and we did not have consent to perform whole genome or whole exome sequencing (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B30" ref-type="bibr">30</xref>). We also did not evaluate other proteins in the lectin pathway of compliment activation (<xref rid="B57" ref-type="bibr">57</xref>). Because most PICFLU patients were white and not Hispanic, our findings are generalizable mainly to that group. Unfortunately, we were unable to identify a similar prospectively enrolled cohort of children with influenza-related critical illness for further independent validation of our findings, which is a major limitation.</p>
              <p>In summary, we conclude that MBL deficiency is not a risk factor for very severe influenza infection in children and adolescents. Children predicted to have MBL deficiency were not at higher risk of more severe critical illness or development of influenza-associated complications such as ALI or bacterial co-infection. We did confirm a previously reported association of higher carriage of the B allele in children that died from influenza-MRSA co-infection, but our confidence in this finding is low due to the small number of patients. It must be noted, that the majority of critical illness from influenza virus at PICFLU sites is preventable by vaccination (<xref rid="B58" ref-type="bibr">58</xref>), which in addition to supportive care and influenza antivirals is currently the most effective way to decrease influenza-related mortality.</p>
            </sec>
            <sec id="s5">
              <title>Preliminary Versions of This Work has Been Presented at the Following Meetings</title>
              <p>PAS 2016: “Mannose-Binding Lectin and Susceptibility to Pediatric Influenza-Related Critical Illness.” Pediatric Academic Societies Annual Meeting, Baltimore, MD. April 2016. Abstract #750580.</p>
              <p>SCCM 2018: “Association of Mannose-Binding Lectin with Influenza Critical Illness in Children.” Society of Critical Care Medicine Annual Meeting, San Antonio, TX. February 2018. Abstract #41.</p>
            </sec>
            <sec id="s6">
              <title>Ethics Statement</title>
              <p>This study was carried out with approval of the Boston Children's Hospital and all participating site Institutional Review Boards with written informed consent from at least one parent or guardian on behalf of the child, and parents consented for their own participation, in accordance with the Declaration of Helsinki. The protocol was approved by the Institutional Review Boards at each enrolling hospital listed in the acknowledgments.</p>
            </sec>
            <sec id="s7">
              <title>Author Contributions</title>
              <p>EL, W-KY, MS, YZ, PALISI PICFLU Investigators, and AR made substantial contributions to the conception or design of the study. EL, W-KY, MS, JF, AM, MN, YZ, HS, GM, AnS, LL, SW, MH, NC, AdS, KT, PALISI PICFLU Investigators, and AR made contributions to the acquisition, analysis, and interpretation of the data for this work. EL, W-KY, MS, and AR drafted the work and JF, YZ, HS, GM, SW, MH, and KT revised it critically for important content. EL, W-KY, MS, JF, AM, YZ, HS, GM, AnS, LL, SW, MH, NC, AdS, KT, PM, PALISI PICFLU Investigators, and AR gave final approval of the version to be published. This work represents the findings and conclusions of the authors and does not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Institutes of Health.</p>
              <sec>
                <title>Conflict of Interest Statement</title>
                <p>MS holds equity in, and consults to, Opsonix Inc. and SlipChip Corp. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ack>
              <p>We would like to acknowledge the essential roles of the following PALISI PICFLU investigators who assisted with sample and data management and with manuscript development: Program Manager Anna Agan, MPH, and Biobank Manager Stephanie Ash, MS. Angela Pansoskaltsis-Mortari, Ph.D. oversaw the evaluation of MBL levels and their quality control. The following PICFLU Investigators at the study sites critically reviewed the initial study proposal and all modifications, and enrolled and collected data on the patients in this study, and critically reviewed the results of the study and their implications: Children's of Alabama, Birmingham, AL (Michele Kong, MD); Arkansas Children's Hospital, Little Rock, AR (Ronald C. Sanders Jr., MD, Glenda Hefley, RN, MNsc); Phoenix Children's Hospital, Phoenix, AZ (David Tellez, MD); Banner Children's/Diamond Children's Medical Center, Tucson, AZ (Katri Typpo, MD); Children's Hospital of Los Angeles, Los Angeles, CA (Barry Markovitz, MD); Children's Hospital Central California, Madera, CA (Ana Lia Graciano, MD); UCSF Benioff Children's Hospital Oakland, Oakland, CA (Heidi Flori, MD, NC, MD); Children's Hospital of Orange County, Orange, CA (Nick Anas, MD, AS, MD, Ofelia Vargas-Shiraishi, BS, CCRC); UCSF Benioff Children's Hospital San Francisco, San Francisco, CA (AS, MD, Patrick McQuillen, MD); Children's Hospital Colorado, Aurora, CO (Angela Czaja, MD, Peter Mourani, MD); Connecticut Children's Medical Center, Hartford, CT (Christopher Carroll, MD, MS); Yale-New Haven Children's Hospital, New Haven, CT (John S. Giuliano Jr., MD, Joana Tala, MD); Holtz Children's Hospital, Miami, FL (Gwenn McLaughlin, MD); Children's Healthcare of Atlanta at Egleston, Atlanta, GA (Matthew Paden, MD, Keiko Tarquinio, MD, Cheryl L. Stone, RN); Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL (Bria M. Coates, MD); The University of Chicago Medicine Comer Children's Hospital, Chicago, IL (Juliane Bubeck Wardenburg, MD, Ph.D., Neethi Pinto, MD); Norton Children's Hospital, Louisville, KY (Vicki Montgomery, MD, FCCM, Janice Sullivan, MD); Boston Children's Hospital, Boston, MA (AR MD, MSc, Anna A. Agan, MPH, Stephanie Ash, MS, Anushay Mistry, BS, Margaret Newhams, MPH); Johns Hopkins Children's Center, Baltimore, MD (Melania Bembea, MD, MPH); Children's Hospital and Clinics of Minnesota, Minneapolis, MN (Stephen C. Kurachek, MD); St. Louis Children's Hospital, St. Louis, MO (Allan Doctor, MD, Mary Hartman, MD); Children's Hospital of Nebraska, Omaha, NE (Edward Truemper, MD, Sidharth Mahapatra, MD, Machelle Dawson, RN, BSN, MEd, CCRC); Children's Hospital at Dartmouth-Hitchcock, Lebanon, NH (Daniel L. Levin, MD, Sholeen Nett, MD, Ph.D., J. Dean Jarvis, MBA, BSN); The Children's Hospital at Montefiore, Bronx, NY (Chhavi Katyal, MD); Golisano Children's Hospital, Rochester, NY (Kate Ackerman, MD, L. Eugene Daugherty, MD); Akron Children's Hospital, Akron, OH (Ryan Nofziger, MD, FAAP); Rainbow Babies and Children's Hospital, Cleveland, OH (Steve Shein, MD); Nationwide Children's Hospital, Columbus, OH (Mark W. Hall, MD, Lisa Steele, RN, BSN, CCRN); Penn State Children's Hospital, Hershey, PA (Neal J. Thomas, MD, Debra Spear, RN); Children's Hospital of Philadelphia, Philadelphia, PA (Julie Fitzgerald, MD, Scott Weiss, MD, Jenny L. Bush, RNC, BSN, Kathryn Graham, BA); Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN (Frederick E. Barr, MD); Dell Children's Medical Center of Central Texas, Austin, TX (Renee Higgerson, MD, LeeAnn Christie, RN); Children's Medical Center, Dallas, TX (Marita Thompson, MD, Cindy Darnell-Bowens, MD); Texas Children's Hospital, Houston, TX (LL, MD, Nancy Jaimon, RN, MSN-Ed); University of Virginia Children's Hospital (Douglas F. Willson, MD); Children's Hospital of Wisconsin, Milwaukee, WI (Rainer Gedeit, MD, Kathy Murkowski, RRT, CCRC); Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada (Philippe A. Jouvet, MD); Centre Hospitalier de l'Université Laval, Quebec, Quebec, Canada (Marc-André Dugas, MD).</p>
            </ack>
            <fn-group>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding.</bold> This work was supported by the National Institutes of Health (NIH AI084011 and HD095228, AR); the Centers for Disease Control and Prevention (CDC, AR); the Intramural Research Program of the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (YZ, HS); and the Boston Children's Hospital Medical Staff Organization House Officer Award (EL). Sequencing reactions were carried out at the DNA Resource Core of Dana-Farber/Harvard Cancer Center (funded in part by National Cancer Institute Cancer Center support grant 2P30CA006516-48).</p>
              </fn>
            </fn-group>
            <sec sec-type="supplementary-material" id="s8">
              <title>Supplementary Material</title>
              <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2019.01005/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2019.01005/full#supplementary-material</ext-link></p>
              <supplementary-material content-type="local-data" id="SM1">
                <media xlink:href="Table_1.DOCX">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SM2">
                <media xlink:href="Table_2.DOCX">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SM3">
                <media xlink:href="Table_3.DOCX">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleischmann-Struzek</surname><given-names>C</given-names></name><name><surname>Goldfarb</surname><given-names>DM</given-names></name><name><surname>Schlattmann</surname><given-names>P</given-names></name><name><surname>Schlapbach</surname><given-names>LJ</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Kissoon</surname><given-names>N</given-names></name></person-group>. <article-title>The global burden of paediatric and neonatal sepsis: a systematic review</article-title>. <source>Lancet Respir Med.</source> (<year>2018</year>) <volume>6</volume>:<fpage>223</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(18)30063-8</pub-id><?supplied-pmid 29508706?><pub-id pub-id-type="pmid">29508706</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>N</given-names></name><name><surname>Wright</surname><given-names>JG</given-names></name><name><surname>Broder</surname><given-names>KR</given-names></name><name><surname>Murray</surname><given-names>EL</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name><name><surname>Glover</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Influenza-associated deaths among children in the United States, 2003-2004</article-title>. <source>N Engl J Med.</source> (<year>2005</year>) <volume>353</volume>:<fpage>2559</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa051721</pub-id><?supplied-pmid 16354892?><pub-id pub-id-type="pmid">16354892</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poehling</surname><given-names>KA</given-names></name><name><surname>Edwards</surname><given-names>KM</given-names></name><name><surname>Weinberg</surname><given-names>GA</given-names></name><name><surname>Szilagyi</surname><given-names>P</given-names></name><name><surname>Staat</surname><given-names>MA</given-names></name><name><surname>Iwane</surname><given-names>MK</given-names></name><etal/></person-group>. <article-title>The underrecognized burden of influenza in young children</article-title>. <source>N Engl J Med.</source> (<year>2006</year>) <volume>355</volume>:<fpage>31</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa054869</pub-id><?supplied-pmid 16822994?><pub-id pub-id-type="pmid">16822994</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>H</given-names></name><name><surname>Brooks</surname><given-names>WA</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Roca</surname><given-names>A</given-names></name><name><surname>Berkley</surname><given-names>JA</given-names></name><name><surname>Madhi</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis</article-title>. <source>Lancet.</source> (<year>2011</year>) <volume>378</volume>:<fpage>1917</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61051-9</pub-id><?supplied-pmid 22078723?><pub-id pub-id-type="pmid">22078723</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawood</surname><given-names>FS</given-names></name><name><surname>Chaves</surname><given-names>SS</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Reingold</surname><given-names>A</given-names></name><name><surname>Meek</surname><given-names>J</given-names></name><name><surname>Farley</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010</article-title>. <source>J Infect Dis.</source> (<year>2014</year>) <volume>209</volume>:<fpage>686</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit473</pub-id><?supplied-pmid 23986545?><pub-id pub-id-type="pmid">23986545</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>AG</given-names></name><name><surname>Vaughn</surname><given-names>F</given-names></name><name><surname>Sullivan</surname><given-names>R</given-names></name><name><surname>Rubinson</surname><given-names>L</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Yoon</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Critically ill children during the 2009-2010 influenza pandemic in the United States</article-title>. <source>Pediatrics.</source> (<year>2011</year>) <volume>128</volume>:<fpage>e1450</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2011-0774</pub-id><?supplied-pmid 22065262?><pub-id pub-id-type="pmid">22065262</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>MW</given-names></name><name><surname>Geyer</surname><given-names>SM</given-names></name><name><surname>Guo</surname><given-names>CY</given-names></name><name><surname>Panoskaltsis-Mortari</surname><given-names>A</given-names></name><name><surname>Jouvet</surname><given-names>P</given-names></name><name><surname>Ferdinands</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Innate immune function and mortality in critically ill children with influenza: a multicenter study</article-title>. <source>Crit Care Med.</source> (<year>2013</year>) <volume>41</volume>:<fpage>224</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e318267633c</pub-id><?supplied-pmid 23222256?><pub-id pub-id-type="pmid">23222256</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancanelli</surname><given-names>MJ</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group>. <article-title>Host genetics of severe influenza: from mouse Mx1 to human IRF7</article-title>. <source>Curr Opin Immunol.</source> (<year>2016</year>) <volume>38</volume>:<fpage>109</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2015.12.002</pub-id><?supplied-pmid 26761402?><pub-id pub-id-type="pmid">26761402</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asgari</surname><given-names>S</given-names></name><name><surname>Schlapbach</surname><given-names>LJ</given-names></name><name><surname>Anchisi</surname><given-names>S</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Bartha</surname><given-names>I</given-names></name><name><surname>Junier</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Severe viral respiratory infections in children with IFIH1 loss-of-function mutations</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2017</year>) <volume>114</volume>:<fpage>8342</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1704259114</pub-id><?supplied-pmid 28716935?><pub-id pub-id-type="pmid">28716935</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamborn</surname><given-names>IT</given-names></name><name><surname>Jing</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Drutman</surname><given-names>SB</given-names></name><name><surname>Abbott</surname><given-names>JK</given-names></name><name><surname>Munir</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Recurrent rhinovirus infections in a child with inherited MDA5 deficiency</article-title>. <source>J Exp Med.</source> (<year>2017</year>) <volume>214</volume>:<fpage>1949</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20161759</pub-id><?supplied-pmid 28606988?><pub-id pub-id-type="pmid">28606988</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>EK</given-names></name><name><surname>Randolph</surname><given-names>AG</given-names></name><name><surname>Bhangale</surname><given-names>T</given-names></name><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Ohlson</surname><given-names>M</given-names></name><name><surname>Oshansky</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans</article-title>. <source>Nat Med.</source> (<year>2017</year>) <volume>23</volume>:<fpage>975</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4370</pub-id><?supplied-pmid 28714988?><pub-id pub-id-type="pmid">28714988</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WC</given-names></name><name><surname>White</surname><given-names>MR</given-names></name><name><surname>Moyo</surname><given-names>P</given-names></name><name><surname>Mcclear</surname><given-names>S</given-names></name><name><surname>Thiel</surname><given-names>S</given-names></name><name><surname>Hartshorn</surname><given-names>KL</given-names></name><etal/></person-group>. <article-title>Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection</article-title>. <source>BMC Immunol.</source> (<year>2010</year>) <volume>11</volume>:<fpage>64</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2172-11-64</pub-id><?supplied-pmid 21182784?><pub-id pub-id-type="pmid">21182784</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartshorn</surname><given-names>KL</given-names></name><name><surname>Sastry</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>MR</given-names></name><name><surname>Anders</surname><given-names>EM</given-names></name><name><surname>Super</surname><given-names>M</given-names></name><name><surname>Ezekowitz</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Human mannose-binding protein functions as an opsonin for influenza A viruses</article-title>. <source>J Clin Invest.</source> (<year>1993</year>) <volume>91</volume>:<fpage>1414</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1172/JCI116345</pub-id><?supplied-pmid 7682571?><pub-id pub-id-type="pmid">7682571</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kase</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Ohtani</surname><given-names>K</given-names></name><name><surname>Eda</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Human mannan-binding lectin inhibits the infection of influenza A virus without complement</article-title>. <source>Immunology.</source> (<year>1999</year>) <volume>97</volume>:<fpage>385</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2567.1999.00781.x</pub-id><?supplied-pmid 10447758?><pub-id pub-id-type="pmid">10447758</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>F</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Sim</surname><given-names>RB</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name></person-group>. <article-title>Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein</article-title>. <source>J Biol Chem.</source> (<year>2004</year>) <volume>279</volume>:<fpage>21302</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M400520200</pub-id><?supplied-pmid 14764589?><pub-id pub-id-type="pmid">14764589</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Morimoto</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>T</given-names></name><name><surname>Nishizono</surname><given-names>A</given-names></name><name><surname>Hirayama</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Entry inhibition of influenza viruses with high mannose binding lectin ESA-2 from the Red alga eucheuma serra through the recognition of viral hemagglutinin</article-title>. <source>Mar Drugs.</source> (<year>2015</year>) <volume>13</volume>:<fpage>3454</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.3390/md13063454</pub-id><?supplied-pmid 26035023?><pub-id pub-id-type="pmid">26035023</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minchinton</surname><given-names>RM</given-names></name><name><surname>Dean</surname><given-names>MM</given-names></name><name><surname>Clark</surname><given-names>TR</given-names></name><name><surname>Heatley</surname><given-names>S</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group>. <article-title>Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population</article-title>. <source>Scand J Immunol.</source> (<year>2002</year>) <volume>56</volume>:<fpage>630</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-3083.2002.01167.x</pub-id><?supplied-pmid 12472676?><pub-id pub-id-type="pmid">12472676</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>DP</given-names></name><name><surname>Dean</surname><given-names>MM</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Marshall</surname><given-names>P</given-names></name><name><surname>Gerns</surname><given-names>N</given-names></name><name><surname>Heatley</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Low mannose-binding lectin function is associated with sepsis in adult patients</article-title>. <source>FEMS Immunol Med Microbiol.</source> (<year>2006</year>) <volume>48</volume>:<fpage>274</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-695X.2006.00144.x</pub-id><?supplied-pmid 17064281?><pub-id pub-id-type="pmid">17064281</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumiya</surname><given-names>M</given-names></name><name><surname>Super</surname><given-names>M</given-names></name><name><surname>Tabona</surname><given-names>P</given-names></name><name><surname>Levinsky</surname><given-names>RJ</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name><etal/></person-group>. <article-title>Molecular basis of opsonic defect in immunodeficient children</article-title>. <source>Lancet.</source> (<year>1991</year>) <volume>337</volume>:<fpage>1569</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(91)93263-9</pub-id><?supplied-pmid 1675710?><pub-id pub-id-type="pmid">1675710</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalia</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>Kamboj</surname><given-names>SS</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name></person-group>. <article-title>A comprehensive in silico analysis of non-synonymous and regulatory SNPs of human MBL2 gene</article-title>. <source>Springerplus.</source> (<year>2016</year>) <volume>5</volume>:<fpage>811</fpage>. <pub-id pub-id-type="doi">10.1186/s40064-016-2543-4</pub-id><?supplied-pmid 27390651?><pub-id pub-id-type="pmid">27390651</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitzeneder</surname><given-names>S</given-names></name><name><surname>Seidel</surname><given-names>M</given-names></name><name><surname>Forster-Waldl</surname><given-names>E</given-names></name><name><surname>Heitger</surname><given-names>A</given-names></name></person-group>. <article-title>Mannan-binding lectin deficiency - good news, bad news, doesn't matter?</article-title><source>Clin Immunol.</source> (<year>2012</year>) <volume>143</volume>:<fpage>22</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2011.11.002</pub-id><?supplied-pmid 22377282?><pub-id pub-id-type="pmid">22377282</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>EC</given-names></name><name><surname>Levy</surname><given-names>ER</given-names></name><name><surname>Madden</surname><given-names>K</given-names></name><name><surname>Agan</surname><given-names>AA</given-names></name><name><surname>Sullivan</surname><given-names>RM</given-names></name><name><surname>Graham</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Mannose-binding lectin levels in critically Ill children with severe infections</article-title>. <source>Pediatr Crit Care Med.</source> (<year>2017</year>) <volume>18</volume>:<fpage>103</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1097/PCC.0000000000001000</pub-id><?supplied-pmid 27820718?><pub-id pub-id-type="pmid">27820718</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>AQ</given-names></name><name><surname>Yue</surname><given-names>CL</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>JW</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Mannose-binding lectin polymorphisms and the risk of sepsis: evidence from a meta-analysis</article-title>. <source>Epidemiol Infect.</source> (<year>2014</year>) <volume>142</volume>:<fpage>2195</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268813003361</pub-id><?supplied-pmid 24398289?><pub-id pub-id-type="pmid">24398289</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera-Ramos</surname><given-names>E</given-names></name><name><surname>Lopez-Rodriguez</surname><given-names>M</given-names></name><name><surname>Ruiz-Hernandez</surname><given-names>JJ</given-names></name><name><surname>Horcajada</surname><given-names>JP</given-names></name><name><surname>Borderias</surname><given-names>L</given-names></name><name><surname>Lerma</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection</article-title>. <source>Crit Care.</source> (<year>2014</year>) <volume>18</volume>:<fpage>R127</fpage>. <pub-id pub-id-type="doi">10.1186/cc13934</pub-id><?supplied-pmid 24950659?><pub-id pub-id-type="pmid">24950659</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zogheib</surname><given-names>E</given-names></name><name><surname>Nyga</surname><given-names>R</given-names></name><name><surname>Cornu</surname><given-names>M</given-names></name><name><surname>Sendid</surname><given-names>B</given-names></name><name><surname>Monconduit</surname><given-names>J</given-names></name><name><surname>Jounieaux</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Prospective Observational Study on the association between serum mannose-binding lectin levels and severe outcome in critically Ill patients with pandemic influenza type A (H1N1) infection</article-title>. <source>Lung.</source> (<year>2018</year>) <volume>196</volume>:<fpage>65</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s00408-017-0067-5</pub-id><?supplied-pmid 29273833?><pub-id pub-id-type="pmid">29273833</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Shang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Tong</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>. <article-title>Lower mannose-binding lectin contributes to deleterious H1N1 2009 infection in children</article-title>. <source>Apmis.</source> (<year>2014</year>) <volume>122</volume>:<fpage>136</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/apm.12111</pub-id><?supplied-pmid 23755909?><pub-id pub-id-type="pmid">23755909</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferdinands</surname><given-names>JM</given-names></name><name><surname>Denison</surname><given-names>AM</given-names></name><name><surname>Dowling</surname><given-names>NF</given-names></name><name><surname>Jost</surname><given-names>HA</given-names></name><name><surname>Gwinn</surname><given-names>ML</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A pilot study of host genetic variants associated with influenza-associated deaths among children and young adults</article-title>. <source>Emerg Infect Dis.</source> (<year>2011</year>) <volume>17</volume>:<fpage>2294</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.3201/eid1712.111002</pub-id><?supplied-pmid 22172537?><pub-id pub-id-type="pmid">22172537</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group> (<year>2017</year>). <source>WHO Public Health Research Agenda for Influenza: 2017 Update.</source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/resources/research/en/">https://www.who.int/influenza/resources/research/en/</ext-link> (accessed June 26, 2018). Licence: CC BY-NC-SA 3.0 IGO.</mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keizer</surname><given-names>MP</given-names></name><name><surname>Wouters</surname><given-names>D</given-names></name><name><surname>Schlapbach</surname><given-names>LJ</given-names></name><name><surname>Kuijpers</surname><given-names>TW</given-names></name></person-group>. <article-title>Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBL-substitution therapy</article-title>. <source>Mol Immunol.</source> (<year>2014</year>) <volume>61</volume>:<fpage>174</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2014.06.005</pub-id><?supplied-pmid 25044097?><pub-id pub-id-type="pmid">25044097</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>AG</given-names></name><name><surname>Yip</surname><given-names>WK</given-names></name><name><surname>Allen</surname><given-names>EK</given-names></name><name><surname>Rosenberger</surname><given-names>CM</given-names></name><name><surname>Agan</surname><given-names>AA</given-names></name><name><surname>Ash</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Evaluation of IFITM3 rs12252 association with severe pediatric influenza infection</article-title>. <source>J Infect Dis.</source> (<year>2017</year>) <volume>216</volume>:<fpage>14</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jix242</pub-id><?supplied-pmid 28531322?><pub-id pub-id-type="pmid">28531322</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>AG</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Novak</surname><given-names>T</given-names></name><name><surname>Newhams</surname><given-names>MM</given-names></name><name><surname>Bubeck Wardenburg</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Vancomycin monotherapy may be insufficient to treat methicillin-resistant <italic>Staphylococcus aureus</italic> coinfection in children with influenza-related critical illness</article-title>. <source>Clin Infect Dis.</source> (<year>2018</year>) <volume>68</volume>:<fpage>365</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy495</pub-id><?supplied-pmid 29893805?><pub-id pub-id-type="pmid">29893805</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>B</given-names></name><name><surname>Giroir</surname><given-names>B</given-names></name><name><surname>Randolph</surname><given-names>A</given-names></name></person-group>. <article-title>International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics</article-title>. <source>Pediatr Crit Care Med.</source> (<year>2005</year>) <volume>6</volume>:<fpage>2</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/01.PCC.0000149131.72248.E6</pub-id><?supplied-pmid 15636651?><pub-id pub-id-type="pmid">15636651</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>MM</given-names></name><name><surname>Patel</surname><given-names>KM</given-names></name><name><surname>Ruttimann</surname><given-names>UE</given-names></name></person-group>. <article-title>PRISM III: an updated Pediatric Risk of Mortality score</article-title>. <source>Crit Care Med.</source> (<year>1996</year>) <volume>24</volume>:<fpage>743</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1097/00003246-199605000-00004</pub-id><?supplied-pmid 8706448?><pub-id pub-id-type="pmid">8706448</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Brigham</surname><given-names>KL</given-names></name><name><surname>Carlet</surname><given-names>J</given-names></name><name><surname>Falke</surname><given-names>K</given-names></name><name><surname>Hudson</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination</article-title>. <source>Am J Respir Crit Care Med.</source> (<year>1994</year>) <volume>149</volume>:<fpage>818</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1164/ajrccm.149.3.7509706</pub-id><?supplied-pmid 7509706?><pub-id pub-id-type="pmid">7509706</pub-id></mixed-citation>
              </ref>
              <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Lindegren</surname><given-names>ML</given-names></name><name><surname>Butler</surname><given-names>MA</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Dowling</surname><given-names>NF</given-names></name><name><surname>Gallagher</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994</article-title>. <source>Am J Epidemiol.</source> (<year>2009</year>) <volume>169</volume>:<fpage>54</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwn286</pub-id><?supplied-pmid 18936436?><pub-id pub-id-type="pmid">18936436</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Super</surname><given-names>M</given-names></name><name><surname>Levinsky</surname><given-names>RJ</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name></person-group>. <article-title>The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations</article-title>. <source>Clin Exp Immunol.</source> (<year>1990</year>) <volume>79</volume>:<fpage>144</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.1990.tb05170.x</pub-id><?supplied-pmid 2311294?><pub-id pub-id-type="pmid">2311294</pub-id></mixed-citation>
              </ref>
              <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selander</surname><given-names>B</given-names></name><name><surname>Martensson</surname><given-names>U</given-names></name><name><surname>Weintraub</surname><given-names>A</given-names></name><name><surname>Holmstrom</surname><given-names>E</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Thiel</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2</article-title>. <source>J Clin Invest.</source> (<year>2006</year>) <volume>116</volume>:<fpage>1425</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1172/JCI25982</pub-id><?supplied-pmid 16670774?><pub-id pub-id-type="pmid">16670774</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>J</surname><given-names>Strøm T</given-names></name><name><surname>Quist</surname><given-names>L</given-names></name><name><surname>Taaning</surname><given-names>E</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name></person-group>. <article-title>Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome</article-title>. <source>J Infect Dis.</source> (<year>2003</year>) <volume>188</volume>:<fpage>1394</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1086/379044</pub-id><?supplied-pmid 14593599?><pub-id pub-id-type="pmid">14593599</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laird</surname><given-names>NM</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group>. <article-title>Implementing a unified approach to family-based tests of association</article-title>. <source>Genet Epidemiol.</source> (<year>2000</year>) <volume>19</volume>(<issue>Suppl. 1</issue>):<fpage>S36</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1002/1098-2272(2000)19:1+&lt;::AID-GEPI6&gt;3.0.CO;2-M</pub-id><?supplied-pmid 11055368?><pub-id pub-id-type="pmid">11055368</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Laird</surname><given-names>NM</given-names></name></person-group>. <article-title>Power calculations for a general class of family-based association tests: dichotomous traits</article-title>. <source>Am J Hum Genet.</source> (<year>2002</year>) <volume>71</volume>:<fpage>575</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1086/342406</pub-id><?supplied-pmid 12181775?><pub-id pub-id-type="pmid">12181775</pub-id></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Demeo</surname><given-names>D</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Laird</surname><given-names>NM</given-names></name></person-group>. <article-title>PBAT: tools for family-based association studies</article-title>. <source>Am J Hum Genet.</source> (<year>2004</year>) <volume>74</volume>:<fpage>367</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/381563</pub-id><?supplied-pmid 14740322?><pub-id pub-id-type="pmid">14740322</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashby</surname><given-names>D</given-names></name></person-group><article-title>Practical statistics for medical research</article-title>. Douglas, G. Altman, Chapman and Hall, London, 1991. <source>Stat Med.</source> (<year>1991</year>) <volume>10</volume>:<fpage>1635</fpage>–<lpage>6</lpage>.</mixed-citation>
              </ref>
              <ref id="B43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Todd-Brown</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><name><surname>Bender</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>. <source>Am J Hum Genet.</source> (<year>2007</year>) <volume>81</volume>:<fpage>559</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1086/519795</pub-id><?supplied-pmid 17701901?><pub-id pub-id-type="pmid">17701901</pub-id></mixed-citation>
              </ref>
              <ref id="B44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>TC</given-names></name><name><surname>Chapman</surname><given-names>S</given-names></name><name><surname>Hutton</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Bion</surname><given-names>J</given-names></name><name><surname>Chiche</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Variants in the mannose-binding lectin gene MBL2 do not associate with sepsis susceptibility or survival in a large European cohort</article-title>. <source>Clin Infect Dis.</source> (<year>2015</year>) <volume>61</volume>:<fpage>695</fpage>–<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ378</pub-id><?supplied-pmid 25969530?><pub-id pub-id-type="pmid">25969530</pub-id></mixed-citation>
              </ref>
              <ref id="B45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atan</surname><given-names>O</given-names></name><name><surname>Kucukcelebi</surname><given-names>A</given-names></name><name><surname>Atik</surname><given-names>T</given-names></name><name><surname>Ozkinay</surname><given-names>F</given-names></name></person-group>. <article-title>Mannose binding lectin codon 54 polymorphism and susceptibility to recurrent respiratory tract infections in children: A meta-analysis</article-title>. <source>Int J Pediatr Otorhinolaryngol.</source> (<year>2016</year>) <volume>81</volume>:<fpage>41</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijporl.2015.11.029</pub-id><?supplied-pmid 26810288?><pub-id pub-id-type="pmid">26810288</pub-id></mixed-citation>
              </ref>
              <ref id="B46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>GJ</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Feng</surname><given-names>ZC</given-names></name></person-group>. <article-title>Low mannose-binding lectin (MBL) levels and MBL genetic polymorphisms associated with the risk of neonatal sepsis: an updated meta-analysis</article-title>. <source>Early Hum Dev.</source> (<year>2014</year>) <volume>90</volume>:<fpage>557</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.earlhumdev.2014.07.007</pub-id><?supplied-pmid 25105751?><pub-id pub-id-type="pmid">25105751</pub-id></mixed-citation>
              </ref>
              <ref id="B47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundbo</surname><given-names>LF</given-names></name><name><surname>Sorensen</surname><given-names>HT</given-names></name><name><surname>Clausen</surname><given-names>LN</given-names></name><name><surname>Hollegaard</surname><given-names>MV</given-names></name><name><surname>Hougaard</surname><given-names>DM</given-names></name><name><surname>Konradsen</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Mannose-binding lectin gene, MBL2, polymorphisms do not increase susceptibility to invasive meningococcal disease in a population of danish children</article-title>. <source>Open Forum Infect Dis.</source> (<year>2015</year>) <volume>2</volume>:<fpage>ofv127</fpage>
<pub-id pub-id-type="doi">10.1093/ofid/ofv127</pub-id><pub-id pub-id-type="pmid">26464842</pub-id></mixed-citation>
              </ref>
              <ref id="B48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundbo</surname><given-names>LF</given-names></name><name><surname>Harboe</surname><given-names>ZB</given-names></name><name><surname>Clausen</surname><given-names>LN</given-names></name><name><surname>Hollegaard</surname><given-names>MV</given-names></name><name><surname>Sorensen</surname><given-names>HT</given-names></name><name><surname>Hougaard</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Mannose-binding lectin gene, MBL2, polymorphisms are not associated with susceptibility to invasive pneumococcal disease in children</article-title>. <source>Clin Infect Dis.</source> (<year>2014</year>) <volume>59</volume>:<fpage>e66</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu276</pub-id><pub-id pub-id-type="pmid">24771334</pub-id></mixed-citation>
              </ref>
              <ref id="B49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darton</surname><given-names>TC</given-names></name><name><surname>Jack</surname><given-names>DL</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Borrow</surname><given-names>R</given-names></name><name><surname>Guiver</surname><given-names>M</given-names></name><name><surname>Kaczmarski</surname><given-names>EB</given-names></name><etal/></person-group>. <article-title>MBL2 deficiency is associated with higher genomic bacterial loads during meningococcemia in young children</article-title>. <source>Clin Microbiol Infect.</source> (<year>2014</year>) <volume>20</volume>:<fpage>1337</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1111/1469-0691.12745</pub-id><?supplied-pmid 24977653?><pub-id pub-id-type="pmid">24977653</pub-id></mixed-citation>
              </ref>
              <ref id="B50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summerfield</surname><given-names>JA</given-names></name><name><surname>Sumiya</surname><given-names>M</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>MW</given-names></name></person-group>. <article-title>Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series</article-title>. <source>Bmj BMJ.</source> (<year>1997</year>) <volume>314</volume>:<fpage>1229</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.314.7089.1229</pub-id><?supplied-pmid 9154025?><pub-id pub-id-type="pmid">9154025</pub-id></mixed-citation>
              </ref>
              <ref id="B51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pascale</surname><given-names>G</given-names></name><name><surname>Cutuli</surname><given-names>SL</given-names></name><name><surname>Pennisi</surname><given-names>MA</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name></person-group>. <article-title>The role of mannose-binding lectin in severe sepsis and septic shock</article-title>. <source>Mediators Inflamm.</source> (<year>2013</year>) <volume>2013</volume>:<fpage>625803</fpage>. <pub-id pub-id-type="doi">10.1155/2013/625803</pub-id><?supplied-pmid 24223476?><pub-id pub-id-type="pmid">24223476</pub-id></mixed-citation>
              </ref>
              <ref id="B52">
                <label>52.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>DP</given-names></name><name><surname>Dean</surname><given-names>MM</given-names></name><name><surname>Boermeester</surname><given-names>MA</given-names></name><name><surname>Fidler</surname><given-names>KJ</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Kronborg</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection</article-title>. <source>Clin Infect Dis.</source> (<year>2008</year>) <volume>47</volume>:<fpage>510</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1086/590006</pub-id><?supplied-pmid 18611155?><pub-id pub-id-type="pmid">18611155</pub-id></mixed-citation>
              </ref>
              <ref id="B53">
                <label>53.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprong</surname><given-names>T</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Neeleman</surname><given-names>C</given-names></name><name><surname>Swinkels</surname><given-names>D</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Van Der Meer</surname><given-names>JW</given-names></name><etal/></person-group>. <article-title>Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock</article-title>. <source>Clin Infect Dis.</source> (<year>2009</year>) <volume>49</volume>:<fpage>1380</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1086/606054</pub-id><?supplied-pmid 19793001?><pub-id pub-id-type="pmid">19793001</pub-id></mixed-citation>
              </ref>
              <ref id="B54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'mahony</surname><given-names>DS</given-names></name><name><surname>Glavan</surname><given-names>BJ</given-names></name><name><surname>Holden</surname><given-names>TD</given-names></name><name><surname>Fong</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>RA</given-names></name><name><surname>Rona</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Inflammation and immune-related candidate gene associations with acute lung injury susceptibility and severity: a validation study</article-title>. <source>PLoS ONE.</source> (<year>2012</year>) <volume>7</volume>:<fpage>e51104</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0051104</pub-id><?supplied-pmid 23251429?><pub-id pub-id-type="pmid">23251429</pub-id></mixed-citation>
              </ref>
              <ref id="B55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilgin</surname><given-names>YM</given-names></name><name><surname>Brand</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>SP</given-names></name><name><surname>Daha</surname><given-names>MR</given-names></name><name><surname>Roos</surname><given-names>A</given-names></name></person-group>. <article-title>Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac surgery: effects of blood transfusions</article-title>. <source>Transfusion.</source> (<year>2008</year>) <volume>48</volume>:<fpage>601</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1537-2995.2007.01585.x</pub-id><?supplied-pmid 18194386?><pub-id pub-id-type="pmid">18194386</pub-id></mixed-citation>
              </ref>
              <ref id="B56">
                <label>56.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frakking</surname><given-names>FN</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><name><surname>Dolman</surname><given-names>KM</given-names></name><name><surname>Van Woensel</surname><given-names>JB</given-names></name><name><surname>Caron</surname><given-names>HN</given-names></name><name><surname>Kuijpers</surname><given-names>TW</given-names></name><etal/></person-group>. <article-title>Mannose-binding lectin (MBL) as prognostic factor in paediatric oncology patients</article-title>. <source>Clin Exp Immunol.</source> (<year>2011</year>) <volume>165</volume>:<fpage>51</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2011.04398.x</pub-id><?supplied-pmid 21488869?><pub-id pub-id-type="pmid">21488869</pub-id></mixed-citation>
              </ref>
              <ref id="B57">
                <label>57.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingels</surname><given-names>C</given-names></name><name><surname>Vanhorebeek</surname><given-names>I</given-names></name><name><surname>Steffensen</surname><given-names>R</given-names></name><name><surname>Derese</surname><given-names>I</given-names></name><name><surname>Jensen</surname><given-names>L</given-names></name><name><surname>Wouters</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>Lectin pathway of complement activation and relation with clinical complications in critically ill children</article-title>. <source>Pediatr Res.</source> (<year>2014</year>) <volume>75</volume>:<fpage>99</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1038/pr.2013.180</pub-id><?supplied-pmid 24129551?><pub-id pub-id-type="pmid">24129551</pub-id></mixed-citation>
              </ref>
              <ref id="B58">
                <label>58.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferdinands</surname><given-names>JM</given-names></name><name><surname>Olsho</surname><given-names>LE</given-names></name><name><surname>Agan</surname><given-names>AA</given-names></name><name><surname>Bhat</surname><given-names>N</given-names></name><name><surname>Sullivan</surname><given-names>RM</given-names></name><name><surname>Hall</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012</article-title>. <source>J Infect Dis.</source> (<year>2014</year>) <volume>210</volume>:<fpage>674</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiu185</pub-id><?supplied-pmid 24676207?><pub-id pub-id-type="pmid">24676207</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
